Authorized Generics as Manufacturer Response to Medicaid Rebate Cap Removal
This cross-sectional study assesses the utilization of branded vs generic dapagliflozin and the financial implications of switching to generics under the Medicaid fee-for-service and managed care organization payment structures. from JAMA Health Forum New Online https://ift.tt/avJnQAV